Recent ENSC News
- Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans • ACCESS Newswire • 03/04/2026 01:45:00 PM
- Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology • ACCESS Newswire • 03/03/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:30:54 PM
- Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength • GlobeNewswire Inc. • 02/27/2026 02:45:46 PM
- Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value • ACCESS Newswire • 02/25/2026 01:00:00 PM
- Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events • ACCESS Newswire • 02/23/2026 01:00:00 PM
- Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain • ACCESS Newswire • 01/28/2026 01:00:00 PM
- Ensysce Biosciences Expands Global Opioid Patent Portfolio • ACCESS Newswire • 01/21/2026 01:00:00 PM
- Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection • ACCESS Newswire • 01/08/2026 01:00:00 PM
- Ensysce Biosciences Issues Annual Shareholder Letter • ACCESS Newswire • 01/05/2026 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/16/2025 09:34:45 PM
- Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid • ACCESS Newswire • 12/09/2025 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/02/2025 09:56:05 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 12/02/2025 06:29:55 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/02/2025 06:26:15 PM
- Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology • ACCESS Newswire • 12/02/2025 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/21/2025 07:21:35 PM
- Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach • ACCESS Newswire • 11/20/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2025 10:29:37 PM
- Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs • ACCESS Newswire • 11/17/2025 01:05:00 PM
- Ensysce Biosciences Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/14/2025 09:15:00 PM
- Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 • ACCESS Newswire • 10/10/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2025 09:02:58 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/02/2025 08:51:22 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/02/2025 08:37:39 PM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
